Komori
M&A and Subsidiary Changes4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Regarding the Third Request for a Response to the Information List Concerning Large-Scale Purchases of the Company’s Shares or Other Securities by Dalton and Others, Who Are Shareholders of the Company

The company made a third request for Dalton and others to provide a response, stating that they continued to refuse to respond to the company’s information list. It also presented the company’s rebuttal and views regarding a statement released by Dalton and others.

Worth reading
15Immaterial
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
30
%(取得を企図していると当社が説明する議決権総数に対する割合)
Wording
Avoiding a definitive answer
How definitive the wording is.

This transaction

ダルトンらが企図する当社株券等の大規模買付行為等
Counterpartyダルトンら(ダルトン・インベストメンツら)
Disclosing companyASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd.Subject of this transaction
This transaction
ItemDetails
Transaction nameダルトンらが企図する当社株券等の大規模買付行為等
Counterparty nameダルトンら(ダルトン・インベストメンツら)
Name of the Subject CompanyASKA Pharmaceutical Holdings Co.,Ltd.
Items this document does not state (29)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceDate of board resolutionContract DateExecution Date / Effective DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

ダルトンらが情報リストへの回答要請を無視する一方で、当社の株主等に向けて一方的な声明を公表しているため。当社は、株主と当社がダルトンらの企図する大規模買付行為等について適切な判断を行えるよう、必要十分な情報提供を求めている。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Third Request for a Response to the Information List Concerning Large-Scale Purchases of the Company’s Shares or Other Securities by Dalton and Others, Who Are Shareholders of the Company | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori